2024-10-05 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis Report

**1. Performance Overview:**

Gilead Sciences Inc. (GILD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines in areas of unmet medical need. Compared to the S&P 500 (VOO), GILD has significantly underperformed with a cumulative return of -12.13% versus 131.45% for VOO. This translates to a current divergence of -143.58, meaning GILD is trailing VOO by 143.58%.  This represents a relative divergence of 7.47%, indicating that GILD's performance is in the bottom 7.47% of its historical performance range compared to VOO.

**2. Recent Price Movements:**

GILD's closing price is currently $84.74. The stock is trading above its 5-day moving average of $83.96, suggesting short-term bullish sentiment.  However, it is below its 20-day ($82.65) and 60-day ($77.46) moving averages, suggesting a potential for further consolidation or downward pressure in the medium to long term. 

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 60.56. This value indicates that the stock is currently in slightly overbought territory, suggesting a potential for a short-term pullback.
* **PPO (Percentage Price Oscillator):** -0.22. This negative value suggests that the stock's momentum is currently bearish.
* **Delta_Previous_Relative_Divergence:** -1.01. This indicates a recent short-term decline in relative performance against the market.
* **Expected Return:** 0.0%. The expected return is currently 0%, suggesting that GILD is not anticipated to outperform VOO over the next 5 years.

**4. Recent Earnings and Outlook:**

GILD's recent earnings have been mixed, with the latest quarter showing improved performance but prior quarters showing weakness. 

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

The most recent earnings report (2024-08-08) exceeded analysts' expectations for both EPS and revenue. GILD's long-term outlook is dependent on the success of its new product pipeline, particularly in the areas of HIV, oncology, and inflammation.

**5. News and Recent Issues:**

* **Recent Market Outlook:** GILD's market performance has been impacted by concerns regarding patent expirations for its key HIV drugs and increased competition in its other therapeutic areas. 
* **Analyst Opinions:** Analyst sentiment on GILD remains mixed, with some expressing cautious optimism about its future prospects while others remain concerned about competitive pressures. 
* **Performance Highlights:** GILD's recent performance has been marked by volatility, reflecting the challenges it faces in adapting its business model to a changing market environment.

**6. Overall Analysis:**

GILD's performance has significantly lagged behind the broader market in recent years. While the recent earnings report showed some improvement, the company still faces challenges related to patent expirations and competition. Technical indicators suggest a potential for short-term consolidation or a pullback. The expected return of 0% indicates that GILD is not anticipated to outperform VOO in the near future. Investors should carefully consider these factors before making any investment decisions. 

**7. Recommendations:**

* **Short-term:**  Due to the slightly overbought RSI and recent short-term decline in relative performance, a cautious approach is recommended in the short-term. 
* **Long-term:**  GILD's long-term prospects are dependent on its ability to successfully develop and commercialize new products. Investors seeking long-term exposure should closely monitor the company's progress in its key therapeutic areas. 
